The antiplatelet agent Plavix (Clopidogrel Bisulfate; BMS/Sanofi Aventis) is the second best selling drug on the market, with sales nearing $8 billion in 2007. Plavix will go generic in 2011 and a much more potent antiplatelet drug called prasugrel (Lilly/Daiichi Sankyo) may soon take its place, or at least that’s what the developers hope to [...]
Filed under: Pharma/Biotech | No Comments »
HDL has long been praised as the “good cholesterol,” as opposed to its evil twin LDL, aka the “bad cholesterol.” Low levels of HDL and high levels of LDL are associated with increased risk of heart disease. High levels of HDL are thought to be protective against heart disease and can offset some of the [...]
Filed under: Pharma/Biotech | No Comments »
Since the controversy over the ENHANCE trial and the drug Vytorin, Schering-Plough’s stock has taken a hit. On April 2nd, the company announced the launch of their productivity and transformation program to confront their new challenges. “We are taking the tough actions that are needed to respond to a tough situation,” said Fred Hassan, Chairman [...]
Filed under: Pharma/Biotech | No Comments »
A US congressional committee is investigating whether the makers of Vytorin knew about the negative results of a key study showing that their expensive drug is no more effective than a cheaper generic.
Vtyorin, a cholesterol drug made by Merck and Schering-Plough Pharmaceuticals is a combination of ezetimibe [...]
Filed under: Pharma/Biotech | No Comments »
